Abstract
Psoriatic disease (PsD) is a spectrum of diseases that affect both skin [cutaneous psoriasis (PsC)] and musculoskeletal features [psoriatic arthritis (PsA)]. A considerable number of patients with PsC have asymptomatic synovio-entheseal inflammations, and approximately one-third of those eventually progress to PsA with an enigmatic mechanism. Published studies have shown that early interventions to the very early-stage PsA would effectively prevent substantial bone destructions or deformities, suggesting an unmet goal for exploring early PsA biomarkers. The emergence of proteomics technologies brings a complete view of all involved proteins in PsA transitions, offers a unique chance to map all potential peptides, and allows a direct head-to-head comparison of interaction pathways in PsC and PsA. This review summarized the latest development of proteomics technologies, highlighted its application in PsA biomarker discovery, and discussed the possible clinical detectable PsA risk factors in patients with PsC.
Highlights
Psoriatic disease (PsD), as an umbrella term, describes a systemic inflammatory disease that predominantly affects the skin [cutaneous psoriasis (PsC)] and musculoskeletal features [psoriatic arthritis (PsA)], with ∼125 million patients worldwide [1, 2]
No biomarkers with a significant difference were found between PsC and PsA, PASI scores were found most strongly correlated to the proteins PI3, IL-17 receptor A, matrix metalloproteinase (MMPs)-1, and SERPING8, when patients with PsA and patients without joint complaints (PsO) belonged to one group
Four proteins including Intercellular adhesion molecule-1 (ICAM1), CC chemokine ligand 18 (CCL18), Dipeptidyl-peptidase 4 (DPP4), Vascular endothelial growth factor D (VEGFD), were found correlate to arthritis activity evaluated by swollen joint count (SJC), among which ICAM-1 and CCL18 were reported relevant to synovial tissue in rheumatoid arthritis activity
Summary
Psoriatic disease (PsD) is a spectrum of diseases that affect both skin [cutaneous psoriasis (PsC)] and musculoskeletal features [psoriatic arthritis (PsA)]. A considerable number of patients with PsC have asymptomatic synovio-entheseal inflammations, and approximately one-third of those eventually progress to PsA with an enigmatic mechanism. Published studies have shown that early interventions to the very early-stage PsA would effectively prevent substantial bone destructions or deformities, suggesting an unmet goal for exploring early PsA biomarkers. The emergence of proteomics technologies brings a complete view of all involved proteins in PsA transitions, offers a unique chance to map all potential peptides, and allows a direct head-to-head comparison of interaction pathways in PsC and PsA. This review summarized the latest development of proteomics technologies, highlighted its application in PsA biomarker discovery, and discussed the possible clinical detectable PsA risk factors in patients with PsC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
